Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and Nivolumab in Advanced Melanoma
NCT04042506Phase 2Withdrawn
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Nov 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in melanoma, sponsored by Sidney Kimmel Comprehensive Cancer Center. Planned start Nov 2019; status: withdrawn.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT04042506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04042506.